The Belgian university, KU Leuven, has joined forces with a small company in Finland to develop new immunotherapies using a proprietary gene expression technology. The Finnish partner is FIT Biotech of Tampere. ---Subscribe to MedNous to access this article--- Regenerative Medicine Company News Finance, Grants, Deals Research & University News
